Stock Events

Stock Events

Strategic Partners A/S 

€92.00
0
-€1.00-1.08% Thursday 06:15

Statistics

Day High
92
Day Low
92
52W High
134.5
52W Low
73
Volume
-
Avg. Volume
-
Mkt Cap
3.84B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4AugExpected
Q1 2023
Q2 2026
-540.99
-540.65
-540.32
-539.99
Expected EPS
N/A
Actual EPS
N/A

Financials

-278.42%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
41,371.74Revenue
-115,186.31Net Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1TB0.MU. It's not an investment recommendation.
Apple
3
AAPL
Realty Income
3
O
Coca-Cola
3
KO
AT&T
3
T

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap32.28B
Biogen is a biotech firm with a strong focus on neurodegenerative diseases, similar to Orphazyme's focus on rare diseases.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in treating cystic fibrosis, a rare disease, showing its capability and interest in the rare disease market.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals focuses on RNAi therapeutics for rare genetic diseases, aligning with Orphazyme's rare disease treatment goals.
Sarepta Therapeutics
SRPT
Mkt Cap2.2B
Sarepta Therapeutics specializes in the treatment of rare genetic diseases, particularly in the area of Duchenne muscular dystrophy.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals is a leader in RNA-targeted drug discovery and development, working on treatments for rare diseases.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the same rare disease space as Orphazyme.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a technology that has the potential to treat the genetic roots of many rare diseases.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk, while known for diabetes care, is expanding into treatments for rare blood disorders, showing its growing interest in the rare disease sector.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio that includes treatments for rare diseases, making it a competitor in the rare disease market space.

About

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative rare diseases. The company offers heat stock proteins that focuses on the treatment of neurodegenerative diseases by harnessing the cell protective properties of the heat shock response, which protects cells from the accumulation of misfolded proteins, aggregated proteins, and dysfunctional lysosomes. Its lead candidate is the Arimoclomol, which is in clinical development for diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, and Inclusion Body Myositis. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
Show more...
CEO
Jakob Færch Bendtsen
Employees
1
Country
Denmark
ISIN
DK0062502894
WKN
000A3EYNB

Listings

CO
DK
STRAP.CO
STU
DE
1TB0.STU
MU
DE
1TB.MU
MU
DE
1TBD.MU

0 Comments

Share your thoughts

FAQ

What is Strategic Partners A/S stock price today?▼
The current price of 1TB0.MU is €92.00 EUR — it has decreased by -1.08% in the past 24 hours. Watch Strategic Partners A/S stock price performance more closely on the chart.
What is Strategic Partners A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Strategic Partners A/S stocks are traded under the ticker 1TB0.MU.
Is Strategic Partners A/S stock price growing?▼
1TB0.MU stock has fallen by -1.6% compared to the previous week, the month change is a -2.13% fall, over the last year Strategic Partners A/S has showed a -31.6% decrease.
What is Strategic Partners A/S market cap?▼
Today Strategic Partners A/S has the market capitalization of 3.84B
When is the next Strategic Partners A/S earnings date?▼
Strategic Partners A/S is going to release the next earnings report on March 03, 2027.
What is Strategic Partners A/S revenue for the last year?▼
Strategic Partners A/S revenue for the last year amounts to 41,371.74 EUR.
What is Strategic Partners A/S net income for the last year?▼
1TB0.MU net income for the last year is -115,186.31 EUR.
How many employees does Strategic Partners A/S have?▼
As of September 04, 2026, the company has 1 employees.
In which sector is Strategic Partners A/S located?▼
Strategic Partners A/S operates in the Health & Wellness sector.
When did Strategic Partners A/S complete a stock split?▼
The last stock split for Strategic Partners A/S was on December 06, 2023 with a ratio of 1:1000.
Where is Strategic Partners A/S headquartered?▼
Strategic Partners A/S is headquartered in Copenhagen, Denmark.